Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A RANDOMIZED PHASE III EVALUATION OF PACLITAXEL + G-CSF + CISPLATIN VERSUS CISPLATIN + 5-FU IN ADVANCED HEAD AND NECK CANCER

NCT00002888 is registered in ClinicalTrials.gov with Eastern Cooperative Oncology Group as lead sponsor.

NCT NCT00002888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A RANDOMIZED PHASE III EVALUATION OF PACLITAXEL + G-CSF + CISPLATIN VERSUS CISPLATIN + 5-FU IN ADVANCED HEAD AND NECK CANCER
Lead sponsor
Eastern Cooperative Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
March 31, 1997
Completion date
August 31, 2004
Enrollment
Not reported
Sites
87

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer